Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis

Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches

(2019) Andrea Berardi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

(2019) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials

(2019) Sinje Gehr et al.   EPMA Journal

Ozanimod for the treatment of relapsing remitting multiple sclerosis

(2018) Ludwig Rasche et al.   EXPERT OPINION ON PHARMACOTHERAPY

Novel Agents for Relapsing Forms of Multiple Sclerosis

(2016) Rebecca Straus Farber et al.   Annual Review of Medicine

Brain health: time matters in multiple sclerosis

(2016) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Optimizing treatment success in multiple sclerosis

(2015) Tjalf Ziemssen et al.   JOURNAL OF NEUROLOGY

Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis

(2015) RJ Fox et al.   VALUE IN HEALTH

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

(2014) John P. DiMarco et al.   Multiple Sclerosis and Related Disorders

Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde

(2012) James Signorovitch et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative Effectiveness Without Head-to-Head Trials

(2010) James E. Signorovitch et al.   PHARMACOECONOMICS